Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Sotatercept for MPN-associated myelofibrosis and anemia

Srdan Verstovsek • 15 Jun 2019
EHA 2019
Anemias Myelofibrosis Myeloproliferative Neoplasms PRM-151 Sotatercept

In this video, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II study of sotatercept (ACE-011) (NCT01712308) for myeloproliferative neoplasm (MPN)-associated myelofibrosis or anemia. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Srdan Verstovsek

An update on the use of navtemadlin in myelofibrosis 1:52
An update on the use of navtemadlin in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis 2:19
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement 2:19
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
Srdan Verstovsek • 7 Dec 2022
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera 1:56
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek • 7 Dec 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals